BW-1014
/ BlueWillow Biologics
- LARVOL DELTA
Home
Next
Prev
1 to 4
Of
4
Go to page
1
August 22, 2024
IN-NE-rH5: A Safety and Immunogenicity of Intranasal Nanoemulsion Adjuvanted Recombinant Pandemic Flu Vaccine in Healthy Adults
(clinicaltrials.gov)
- P1 | N=40 | Completed | Sponsor: BlueWillow Biologics | Active, not recruiting ➔ Completed
Trial completion • Infectious Disease • Influenza • Respiratory Diseases
September 22, 2022
IN-NE-rH5: A Safety and Immunogenicity of Intranasal Nanoemulsion Adjuvanted Recombinant Pandemic Flu Vaccine in Healthy Adults
(clinicaltrials.gov)
- P1 | N=40 | Active, not recruiting | Sponsor: BlueWillow Biologics | Recruiting ➔ Active, not recruiting
Enrollment closed • Infectious Disease • Respiratory Diseases • CD40LG • CD69 • GZMB • IFNG • IL10 • IL2 • IL21 • IL4 • LAMP1
July 11, 2022
IN-NE-rH5: A Safety and Immunogenicity of Intranasal Nanoemulsion Adjuvanted Recombinant Pandemic Flu Vaccine in Healthy Adults
(clinicaltrials.gov)
- P1 | N=40 | Recruiting | Sponsor: BlueWillow Biologics | Not yet recruiting ➔ Recruiting
Enrollment open • Infectious Disease • Respiratory Diseases • CD40LG • CD69 • GZMB • IFNG • IL10 • IL2 • IL21 • IL4 • LAMP1
May 31, 2022
IN-NE-rH5: A Safety and Immunogenicity of Intranasal Nanoemulsion Adjuvanted Recombinant Pandemic Flu Vaccine in Healthy Adults
(clinicaltrials.gov)
- P1 | N=40 | Not yet recruiting | Sponsor: BlueWillow Biologics
New P1 trial • Infectious Disease • Respiratory Diseases • CD40LG • CD69 • GZMB • IFNG • IL10 • IL2 • IL21 • IL4 • LAMP1 • TNFA
1 to 4
Of
4
Go to page
1